Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$49.07 USD
+1.28 (2.68%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $49.07 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
LEGN 49.07 +1.28(2.68%)
Will LEGN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for LEGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LEGN
Mortgage Rates Fall to a 12-Month Low
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed
LEGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
Other News for LEGN
Stock Picks From Seeking Alpha's September 2024 New Analysts
Buy Rating for Legend Biotech: Strategic Expansion and Increased CARVYKTI Production Forecasted to Alleviate Supply Constraints and Drive Growth
Legend Biotech to open cell therapy R&D facility in Philadelphia
Legend Biotech (LEGN) Gets a Buy from Jefferies
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients